TMC125-C206: A PHASE III STUDY TO INVESTIGATE THE EFFICACY, TOLERABILITY AND SAFETY OF TMC125 AS PART OF AN ANTIRETROVIRAL REGIMEN, INCLUDING TMC114/RITONAVIR AND AN INVESTIGATOR-SELECTED OPTIMIZED BACKGROUND, IN HIV-1 INFECTED PATIENTS WITH LIMITED TO NO TREATMENT OPTIONS.: